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and NFPA patients did not show altered novelty-seeking be-
haviour or extraversion. In the subgroup analysis, CD pa-
tients with persistent hypercortisolism displayed significant-
ly higher fear of uncertainty, fatigability and asthenia, indi-
cating high harm avoidance in total, than those in 
biochemical remission.  Conclusion: Patients with CD showed 
a distinct pattern of personality traits associated with high 
anxiety in combination with traits of low externalizing be-
haviour. Such personality changes should be taken into ac-
count in the diagnosis and treatment of CD patients, as they 
might interfere with the patient-physician communication 
and/or challenge the patients’ social and psychological func-
tioning.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Several studies have focussed on psychopathological 
and personality changes associated with pituitary lesions 
 [1] . In our previous work  [2] , we reported increased anx-
iety-related personality traits in combination with re-
duced externalizing traits in patients with acromegaly 
compared to the general population. Patients with non-
functioning pituitary adenomas (NFPA) also reported el-
evated anxiety-related traits in this study, while no differ-
ences were observed in externalizing traits.
 Key Words 
 Personality   Cushing’s disease   Non-functioning pituitary 
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 Abstract 
 Background/Aims: Chronic hypercortisolism in Cushing’s 
disease (CD) has been suggested to contribute to an altered 
personality profile in these patients. We aimed to test this 
hypothesis and attempted to determine the effects of dis-
ease- and treatment-related factors that might moderate an 
altered personality in CD.  Methods: We assessed 50 patients 
with CD (74% biochemically controlled) and compared them 
to 60 patients with non-functioning pituitary adenomas 
(NFPA) and 100 age- and gender-matched mentally healthy 
controls. Personality was measured by two standardized 
personality questionnaires, TPQ (Cloninger Personality Ques-
tionnaire) and EPQ-RK (Eysenck Personality Question-
naire-RK).  Results: Compared to mentally healthy controls, 
CD patients reported significantly less novelty-seeking be-
haviour, including less exploratory excitability and less ex-
travagance. On harm avoidant subscales, they presented 
with more anticipatory worries and pessimism, higher fear of 
uncertainty, shyness with strangers, fatigability and asthe-
nia. Moreover, CD patients appeared to be less extraverted, 
more neurotic and socially desirable. CD patients differed 
from NFPA patients in terms of higher neuroticism scores, 
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 A large number of studies in humans and animal 
models have documented the interaction of glucocorti-
coids and the central nervous system via the hippocam-
pus  [3] , suggesting a glucocorticoid component in com-
mon psychiatric disorders such as anxiety, depression 
and insomnia  [4–6] . Through these central effects, it is 
conceivable that in Cushing’s disease (CD), a state of 
chronic hypercortisolism, personality might be altered.
 Several previous studies have investigated personality 
dimensions in CD so far  [7–12] . Anxiety seems to be more 
pronounced in patients with CD than in patients with 
adrenal causes of hypercortisolism, suggesting the im-
portance of the pituitary mass per se  [13] . After correc-
tion of hypercortisolism, psychopathology gradually im-
proves  [14] . However, comparable to long-term impair-
ment of quality of life  [15, 16] , an increased prevalence of 
psychopathology and maladaptive personality traits per-
sists even after long-term cure of CD, suggesting irrevers-
ible effects of previous glucocorticoid excess on the cen-
tral nervous system rather than a direct effect of pituitary 
tumours and/or their treatment per se, as recently report-
ed  [9] .
 Since an anxiety-associated personality profile for CD 
has been described, we aimed to verify this hypothesis 
and attempted to determine the effects of disease- and 
treatment-related factors that might contribute to these 
personality traits. To test this hypothesis, we employed 
two standardized personality questionnaires, the Clon-
inger Personality Questionnaire (TPQ) and the short ver-
sion of the revised Eysenck Personality Questionnaire-
RK (EPQ-RK)  [2] . To exclude the possibility that pitu-
itary adenomas and/or their treatment are associated 
with anxiety-associated personality traits, we contrasted 
CD patients against a clinical control group with NFPA 
and age- and gender-matched mentally healthy controls.
 Subjects and Methods 
 Participants 
 Ninety-two patients with previously diagnosed CD treated at 
the Max Planck Institute of Psychiatry and the Medizinische 
Klinik Innenstadt, Ludwig-Maximilians-University, were invited 
to participate in this study (response rate 54%). As a clinical con-
trol group, we recruited 60 patients with NFPA treated previous-
ly by transsphenoidal surgery (response rate 60%). As a mentally 
healthy control group, we sampled 100 age- and gender-matched 
controls (ratio 1: 2) recruited within the Munich Antidepressants 
Response Signature project. Since matching for age could not be 
exact, we considered a number of  8 3 years acceptable for a match. 
Absence of a history of mental disorders was verified with a mod-
ified version of the Munich-Composite-Diagnostic Interview 
 [17] , and absence of severe internal diseases was evaluated with a 
structured interview and by questionnaire. All subjects gave their 
written informed consent. The study was approved by the local 
ethical committee.
 Assessment of Personality 
 Personality traits in the three study groups were assessed using 
two questionnaires, the German versions of the EPQ-RK and the 
TPQ.
 The EPQ-RK comprises 50 items to be answered in a binary 
mode as ‘yes’/‘no’  [18] . The responses define three independent 
personality dimensions: (i) psychoticism defined as cold, imper-
sonal, lacking in sympathy, emotionality, empathy and insight 
combined with a tendency of paranoid ideas against oneself; (ii) 
extraversion characterized by enjoyment of social interactions 
and in novel activities and a tendency towards impulsive behav-
iour, and (iii) neuroticism defined by feelings of anxiety, de-
pressed mood and guilt. These personality dimensions are com-
plemented by a social desirability scale evaluating the tendency to 
respond in a manner that is assumed to be viewed favourably by 
others.
 The TPQ encompasses 100 items describing statements about 
habitual behaviour, which can be answered in a binary mode as ‘I 
do agree’/ ‘I do not agree’  [19] . The responses are summarized 
with respect to three dimensions of personality: novelty seeking 
(TPQ-NS) representing the heritable tendency toward explorato-
ry activity and intense excitement to novel stimuli, harm avoid-
ance (TPQ-HA) as heritable tendency to respond intensively to 
aversive stimuli and to learn to avoid punishment, and novelty 
and situations of non-reward and reward dependence (TPQ-RD) 
reflecting the heritable tendency to respond intensively to reward 
and succorance and to learn to maintain rewarded behaviour. 
These personality dimensions can be further subdivided into sub-
scales, which are (i) exploratory excitability (TPQ-NS1), impul-
siveness (TPQ-NS2), extravagance (TPQ-NS3) and disorderliness 
(TPQ-NS4) within the novelty-seeking dimension; (ii) anticipa-
tory worries and pessimism (TPQ-HA1), fear of uncertainty 
(TPQ-HA2), shyness with strangers (TPQ-HA3) and fatigability 
and asthenia (TPQ-HA4) within harm avoidance, and (iii) senti-
mentality (TPQ-RD1), persistence (TPQ-RD2), attachment 
(TPQ-RD3) and dependence (TPQ-RD4) within reward depen-
dence.
 The EPQ-RK and TPQ show substantial correlations between 
some subscales such as novelty seeking and extraversion (r = 0.53), 
suggesting representation of a common trait of externalizing be-
haviour; also, harm avoidance and neuroticism correlate with 
each other (r = 0.6), describing a common trait of an anxiety-re-
lated personality  [20] .
 Assessment of Comorbidities, Biochemical Variables and 
Covariates 
 Clinical characteristics of the subjects were collected with re-
gard to disease history, tumour characteristics, previous and cur-
rent therapy, and comorbidities as well as current complaints. Co-
morbidities were diagnosed and treated according to the respec-
tive guidelines.
 Diagnosis of CD was confirmed by histological examination 
following transsphenoidal exploration of the pituitary. Therapies 
used to treat CD followed the current consensus treatment algo-
rithm  [21] . Transsphenoidal surgery with selective pituitary tu-
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mour resection represented the treatment of choice. Second-line 
treatments included more radical surgery, radiation therapy, 
medical therapy and bilateral adrenalectomy.
 Diagnostic criteria suggestive of hypercortisolism after treat-
ment for CD were (a) urinary free cortisol level greater than the 
normal range for the assay, and (b) serum cortisol greater than 1.8 
g/dl (50 nmol/l) after 1 mg dexamethasone  [22] . Thirteen patients 
(26%) did not fulfil the criteria of biochemical control at study 
time point.
 Pituitary function was assessed in both patient groups at year-
ly intervals and a maximum of  8 3 months in relation to the tim-
ing of the questionnaires. Evaluation of pituitary function com-
prised basal fasting measurements of IGF1, TSH, free thyroxine, 
total triiodothyronine, LH, FSH, prolactin and testosterone (in 
men) or oestradiol (in women) in all patients, as well as stimula-
tion tests such as a short ACTH test or the GHRH/arginine test in 
the case of suspected pituitary deficiencies in the corticotropic or 
somatotropic axis  [23] . All CD patients with secondary hypoad-
renalism, hypothyroidism, hypogonadism and hyposomatotro-
pism (56, 42, 20 and 28%, respectively) and all NFPA patients with 
secondary hypoadrenalism, hypothyroidism, hypogonadism and 
hyposomatotropism (44, 43, 38 and 43%, respectively) were stud-
ied while on optimized replacement therapy  [23] . In the case of 
hypoadrenalism, this included substitution with 10–25 mg hydro-
cortisone per day (2–3 doses per day).
 Statistical Analysis 
 Statistical analysis was performed using SPSS Version 17 for 
Windows. Sample characteristics were compared using   2 tests 
and analysis of variance. Differences in personality between CD 
patients, mentally healthy controls and the clinical control group 
of NFPA patients were evaluated with an analysis of covariance 
(ANCOVA) controlling for age, gender, arterial hypertension and 
diabetes mellitus, characteristics that differed between the three 
groups. In the case of group differences, post hoc tests, corrected 
for multiple comparisons following the Bonferroni-Holm proce-
dure, were applied (level of significance 0.05). In addition, we ap-
plied ANCOVA controlling for age and gender to evaluate person-
ality differences between biochemically controlled and uncon-
trolled CD patients, between hypopituitary patients and patients 
with normal pituitary function, between radiated and non-radi-
ated CD patients or dependent on disease duration ( 1 median vs. 
 ! median). Differences were considered statistically significant at 
p  ! 0.05. Missing values for single questions about clinical comor-
bidity were changed into zero, hypothesizing that patients in-
volved most likely did not experience this symptom or comorbid-
ity. Missing values in the personality questionnaires were esti-
mated by the respective individual scale mean (if the number of 
missing items is not exceeding 10%).
 Results 
 Demographic and Clinical Characteristics of the Study 
Group 
 In the CD patient group (n = 50, 82% female), the mean 
age was 46.36  8 11.63 years. The majority of the CD pa-
tients (38% with microadenomas) had been previously 
operated (98%; mean time after surgery 115.2  8 14.7 
months). Thirteen patients (26%) were irradiated and 5 
patients received medical treatment with ketoconazole 
(10%). The mean time after radiotherapy was 84.1  8 17.4 
months. CD patients suffered from pituitary deficiency 
(64%), arterial hypertension (60%), arthralgia (50%), dia-
betes mellitus (22%) and arrhythmias (18%). CD was bio-
chemically controlled in 37 patients (74%) at the time of 
the study. The mean time after biochemical remission 
was 85.75  8 39.0 months. The mean actual 24-hour uri-
nary free cortisol was 213.6  8 63.4   g (reference range 
for the used assay 20.9–292.3   g/24 h).
 CD patients differed from NFPA patients in gender, 
age, adenoma type and comorbidities. Compared to 
NFPA patients, there were significantly more female CD 
patients (82 vs. 35%; p  ! 0.001). CD patients were signifi-
cantly younger (46.4  8 11.6 vs. 60.2  8 10.6 years; p  ! 
0.001), with a lower prevalence of macroadenomas (20 vs. 
83%; p  ! 0.001).
 Table 1 presents demographic and clinical character-
istics of the study groups.
 Profile of Personality Traits in CD Patients
Compared to Mentally Healthy Control Subjects and 
NFPA Patients 
 Compared to mentally healthy controls, CD patients 
reported significantly less novelty-seeking behaviour 
(TPQ-NS; p  ! 0.001), which can be described by low ex-
ploratory excitability (TPQ-NS1; p  ! 0.001) and low ex-
travagance (TPQ-NS3; p = 0.015). On harm avoidant sub-
scales, CD patients presented with more anticipatory 
worries and pessimism (TPQ-HA1; p  ! 0.001), higher 
fear of uncertainty (TPQ-HA2; p  ! 0.001), shyness with 
strangers (TPQ-HA3; p  ! 0.001), and fatigability and as-
thenia (TPQ-HA4; p  ! 0.001), indicating high harm 
avoidance in total (TPQ-HA; p  ! 0.001). CD patients did 
not appear to be more reward dependent in total (TPQ-
RD; p  1 0.05); moreover, there were no significant differ-
ences between the two groups in the subscales sentimen-
tality, persistence, attachment or dependence. Regarding 
the three personality dimensions as defined by the EPQ-
RK, CD patients appeared to be more neurotic (EPQ-N; 
p  ! 0.001) and socially desirable (EPQ-SD; p = 0.040), but 
less extraverted (EPQ-E; p = 0.003) when compared to a 
mentally healthy population.
 Elevated scores in harm avoidance (TPQ-HA; p  ! 
0.001), social desirability (EPQ-SD; p  ! 0.001) and neu-
roticism (EPQ-N; p  ! 0.001) could also be documented in 
NFPA patients when compared to the mentally healthy 
control subjects. No differences were observed for nov-
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elty seeking (TPQ-NS) and extraversion (EPQ-E), while 
CD patients presented with reduced scores on these scales 
when compared with mentally healthy controls. Specific 
differences for CD patients were found with respect to 
neuroticism (EPQ-N), with the highest scores observed 
in CD, followed by significantly lower scores in NFPA 
patients (p = 0.003), which still were higher than those 
observed in mentally healthy controls (p  ! 0.001).
 Table 2 presents personality traits of the study groups.
 Subgroup Analysis of Patients with CD 
 To evaluate personality differences between biochemi-
cally controlled and uncontrolled CD patients, between 
hypopituitary patients and patients with normal pituitary 
function, between radiated and non-radiated CD patients 
or dependent on disease duration ( 1 median vs.  ! median), 
we additionally applied ANCOVA controlling for age and 
gender. Since chronic pain might be a factor altering the 
patients’ personality profile, we additionally conducted a 
subgroup analysis in patients with and without arthralgia.
 CD patients with persistent cortisol excess presented 
with significantly higher fear of uncertainty (TPQ-HA2; 
p = 0.008) and fatigability and asthenia (TPQ-HA4; p = 
0.034), indicating high harm avoidance in total (TPQ-
HA; p = 0.036) when compared with biochemically con-
trolled CD patients. Furthermore, hypopituitary patients 
appeared to be more shy with strangers (TPQ-HA3; p = 
0.011) in comparison to patients with normal pituitary 
function. No further statistically significant differences 
(p  ! 0.05) could be detected in any of these comparisons.
Table 1.  Demographic and clinical characteristics of the study groups including 50 CD patients, 100 age- and gender-matched men-
tally healthy controls and 60 NFPA patients
Mentally healthy
controls (1)
NFPA (2) CD (3) G lobal test p value (Bonferroni-Holm-
corrected post hoc tests)
2/ANOVA p value 1 vs. 2 2 vs. 3 1 vs. 3
Gender
Male 18 (18) 39 (65) 9 (18)
Female 82 (82) 21 (35) 41 (82) 43.93 <0.001 <0.001 <0.001 n.s.
Age, years 46.36811.57 60.22810.61 46.36811.63 32.10 (ANOVA) <0.001 <0.001 <0.001 n.s.
Primary adenoma type
Macroadenoma n.a. 50 (83) 10 (20) <0.001 <0.001
Microadenoma n.a. 4 (7) 19 (38)
Unknown size n.a. 6 (10) 21 (42)
Treatment
Surgery n.a. 52 (87) 49 (98)
Radiotherapy n.a. 15 (25) 13 (26)
Medical therapy n.a. 0 5 (10)
Comorbidities
Arrhythmias 0 3 (5) 9 (18)
Cardiomyopathy 0 0 1 (2)
Cerebrovascular disease 0 3 (5) 1 (2)
Hypertension 16 (16) 27 (45) 30 (60) 35.01 <0.001 n.s. <0.001 <0.001
Coronary artery disease 0 2 (3) 0
Myocardial infarction 0 1 (2) 0
Arthralgia 0 25 (42) 25 (50)
Arthropathy 0 9 (15) 11 (22)
Carpal tunnel syndrome 0 11 (18) 9 (18)
Diabetes mellitus 2 (2) 6 (10) 11 (22) 17.48 <0.001 n.s. 0.038 <0.001
Pituitary deficiency n.a. 45 (75) 32 (64)
Hyperprolactinaemia n.a. 2 (3.3) 0
Sleep apnea 0 6 (10) 3 (6)
Other lung diseases 0 1 (2) 3 (6)
Malignancies 5 (5) 6 (10) 3 (6)
Val ues are means 8 SD or numbers with percentages in parentheses. n.s. = Nonsignificant; n.a. = not applicable.
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 Discussion 
 We aimed to verify the observation that an anxiety-
associated personality profile exists for CD and attempt-
ed to determine factors that might contribute to these 
personality traits. To address this issue, we employed two 
standardized personality questionnaires. To exclude the 
possibility that pituitary adenomas per se and/or their 
treatment might be associated with anxiety-related per-
sonality traits, we employed a clinical control group com-
prising NFPA patients.
 This study demonstrates that CD patients are charac-
terized by a pattern of elevated anxiety-related personal-
ity traits, TPQ harm avoidance and EPQ-RK neuroti-
cism, in combination with reduced scores in externaliz-
ing traits, TPQ novelty seeking and extraversion. This is 
a typical pattern we have previously observed in acrome-
galic patients  [2] , while NFPA patients serving as clinical 
control group described themselves by lower – albeit still 
elevated – neuroticism scores and reported unchanged 
scores in externalizing traits compared with the mental-
ly healthy controls.
 Our results are in accordance with the recently pub-
lished findings by Tiemensma et al.  [9] , who observed 
prevalence of ‘maladaptive’ traits in CD, even after long-
term cure. In agreement with these findings, we observed 
elevated scores in anxiety-related traits as well as reduced 
scores in externalizing traits, which corresponds to high-
er scores on social avoidance as reported by Tiemensma 
et al.  [9] . As anticipated, anxiety-related personality traits 
including higher scores on harm avoidance in total, but 
also on the subscales fear of uncertainty and fatigability 
and asthenia, were clearly associated with persistent cor-
tisol excess.
 Regarding treatment- and disease-related factors that 
might contribute to the observed personality profile, we 
did not observe any significant differences between radi-
ated and non-radiated CD patients or dependent on dis-
Table 2.  Personality traits of the study groups
Mentally
healthy
controls (1)
NFPA (2) CD (3) ANCOVA p value (Bonferroni-Holm-
c orrected post hoc tests)
F(2, 18) p value 1 vs. 3 2 vs. 3 1 vs. 2
TPQ
TPQ novelty seeking total (TPQ-NS) 16.4584.45 13.4984.83 13.7483.99 7.60 0.001 <0.001 n.s. n.s.
TPQ harm avoidance total (TPQ-HA) 10.3385.48 15.6386.81 19.9486.69 35.36 <0.001 <0.001 n.s. <0.001
TPQ reward dependence total (TPQ-RD) 17.3284.29 15.5683.69 17.4484.04 0.34 n.s. n.s. n.s. n.s.
TPQ exploratory excitability (TPQ-NS1) 4.7181.71 3.6581.83 3.4881.75 6.83 0.001 <0.001 n.s. n.s.
TPQ impulsiveness (TPQ-NS2) 3.8781.76 3.4482.12 3.3081.95 2.63 n.s. n.s. n.s. n.s.
TPQ extravagance (TPQ-NS3) 4.3181.54 3.3781.50 3.7481.76 4.32 0.015 0.015 n.s. n.s.
TPQ disorderliness (TPQ-NS4) 3.5681.68 3.0081.57 3.2481.36 0.87 n.s. n.s. n.s. n.s.
TPQ anticipatory worries
and pessimism (TPQ-HA1) 3.0882.12 4.2582.49 5.6882.19 22.95 <0.001 <0.001 n.s. <0.001
TPQ fear of uncertainty (TPQ-HA2) 3.3281.87 4.4081.82 5.3081.62 15.15 <0.001 <0.001 n.s. 0.002
TPQ shyness with strangers (TPQ-HA3) 2.1481.71 2.8281.86 3.6281.69 8.95 <0.001 <0.001 n.s. n.s.
TPQ fatigability and asthenia (TPQ-HA4) 1.7881.70 4.1482.66 5.3483.01 36.58 <0.001 <0.001 n.s. <0.001
TPQ sentimentality (TPQ-RD1) 3.8881.23 3.9581.17 4.2280.86 1.79 n.s. n.s. n.s. n.s.
TPQ persistence (TPQ-RD2) 3.7482.10 3.5481.86 4.2482.03 1.32 n.s. n.s. n.s. n.s.
TPQ attachment (TPQ-RD3) 6.7082.64 5.7082.28 6.0882.30 0.90 n.s. n.s. n.s. n.s.
TPQ dependence (TPQ-RD4) 3.0081.35 2.3781.41 2.9281.61 0.20 n.s. n.s. n.s. n.s.
EPQ-RK
EPQ-RK psychoticism (EPQ-P) 1.9681.68 1.3481.46 1.6081.46 1.24 n.s. n.s. n.s. n.s.
EPQ-RK extraversion (EPQ-E) 7.5583.32 5.9183.84 5.3283.68 5.21 0.006 0.003 n.s. n.s.
EPQ-RK neuroticism (EPQ-N) 2.8482.20 4.0282.80 6.4883.39 29.67 <0.001 <0.001 0.003 <0.001
EPQ-RK social desirability (EPQ-SD) 3.2082.42 5.7682.75 4.0482.42 7.40 0.001 0.040 n.s. <0.001
Va lues are means 8 SD. Results of the EPQ-RK and the TPQ are compared between groups using ANCOVA controlling for age, 
gender, arterial hypertension and diabetes mellitus. Bonferroni-Holm-corrected post hoc tests for two-group comparisons are per-
formed in the case of significant differences in the global ANCOVA. n.s.  = Nonsignificant.
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ease duration ( 1 median vs.  ! median; p  1 0.05), suggest-
ing CD per se as the underlying cause of the observed 
traits. Hypopituitarism was positively associated with 
higher shyness with strangers as measured by the corre-
sponding subscale of the TPQ. Tiemensma et al.  [9] com-
parably reported a positive correlation between hypopi-
tuitarism and suspiciousness, but also between addition-
al radiotherapy and hydrocortisone dependency with 
identity problems and between longer duration of remis-
sion and higher scores on the self-harm subscale. Fur-
thermore, negative illness perceptions might contribute 
to an impaired quality of life in patients after long-term 
remission of CD, as recently stated by Tiemensma et al. 
 [9] ; however, we did not investigate this systematically 
 [24] .
 We can only speculate as to why CD patients exhibit 
the reported pattern of elevated anxiety traits (harm 
avoidance and neuroticism) in combination with reduced 
externalizing traits (novelty seeking and extraversion). A 
possible explanation could be an impaired cortical or 
subcortical integrity due to the chronic cortisol excess in 
CD, which might translate into an altered personality 
pattern as observed in our study. This speculation is sup-
ported by the finding of cerebral atrophy and decreased 
hippocampal volume in CD patients  [25] . Especially the 
hippocampal region has been discussed to be linked with 
CD as both a target for the deleterious effects of chronic 
glucocorticoid exposure cortisol and a region modulat-
ing the personality. Martin et al.  [26] have been able to 
show a positive correlation between externalizing behav-
iour traits in terms of experience seeking and hippocam-
pus volume, and particularly with the anterior portion of 
the right hippocampal grey matter. When taking into ac-
count that the observation of reduced externalizing traits 
in terms of low novelty seeking and extraversion was spe-
cific for CD, one might speculate that changes in these 
traits might be a potential endophenotype for hippocam-
pal impairment due to chronic glucocorticoid excess.
 As a limitation of our study, we have to mention the 
cross-sectional design, which limits the possibility to 
draw conclusions on causal interferences between CD-
associated changes and the development of an altered 
personality. Furthermore, we have to take into consider-
ation that state variables such as depression, which is 
common in CD, might have influenced personality trait 
assessment. Depression data are, unfortunately, not avail-
able. However, the personality questionnaires applied in 
this study have been designed for being robust against 
state effects to give a reliable picture of stable personality 
traits.
 In conclusion, CD patients show a distinct pattern of 
personality traits associated with high anxiety in combi-
nation with traits of low externalizing behaviour, compa-
rable with acromegalic patients, but only in part with 
NFPA patients. Persistent cortisol excess and the pres-
ence of hypopituitarism, but not previous radiation ther-
apy or duration of active hypercortisolism, were partially 
associated with this personality profile. The reported 
personality pattern might constitute an additional chal-
lenge for diagnosis and therapy of CD, and might contrib-
ute to impaired social and psychological functioning and 
well-being.
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